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Abstract 
 
Survival rates for pancreatic cancer patients have remained unchanged for the last four decades. The 
most aggressive, and most common, type of pancreatic cancer is pancreatic ductal adenocarcinoma 
(PDAC), which has the lowest 5-year survival rate of all cancers globally. The poor prognosis is 
typically due to late presentation of often non-specific symptoms and rapid development of resistance 
to all current therapeutics, including the standard-of-care cytotoxic drug gemcitabine. While early 
surgical intervention can significantly prolong patient survival, there are few treatment options for 
late-stage non-resectable metastatic disease, resulting in mostly palliative care. In addition, a defining 
feature of pancreatic cancer is the immunosuppressive and impenetrable desmoplastic stroma that 
blocks access to tumour cells by therapeutic drugs. The limited effectiveness of conventional 
chemotherapeutics reveals an urgent need to develop novel therapies with different mechanisms of 
action for this malignancy.  
 
An emerging alternative to current therapeutics is oncolytic adenoviruses; these engineered biological 
agents have proven efficacy and tumour-selectivity in preclinical pancreatic cancer models, including 
models of drug-resistant cancer. Safety of oncolytic adenoviral mutants has been extensively assessed 
in clinical trials with only limited toxicity to normal healthy tissue being reported.  Promising efficacy 
in combination with gemcitabine was demonstrated in preclinical and clinical studies. A recent surge 
in novel adenoviral mutants entering clinical trials for pancreatic cancer indicates improved efficacy 
through activation of the host anti-tumour responses. The potential for adenoviruses to synergise with 
chemotherapeutics, activate anti-tumour immune responses, and contribute to stromal dissemination 
render these mutants highly attractive candidates for improved patient outcomes.  
 
Currently, momentum is gathering towards the development of systemically-deliverable mutants that 
are able to overcome anti-viral host immune responses, erythrocyte binding and hepatic uptake, to 
promote elimination of primary and metastatic lesions. This review will cover the key components of 
pancreatic cancer oncogenesis; novel oncolytic adenoviruses; clinical trials; and the current progress 
in overcoming the challenges of systemic delivery. 
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Introduction 
 
Pancreatic cancer is the fourth leading cause of cancer-related deaths globally, even though it 
accounts for only 3% of all cancer diagnoses in the Western world [1]. Survival rates for the most 
aggressive form of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), have not improved 
significantly since the 1980s [2]. The prognosis for PDAC patients remains unacceptably poor, owing 
to the fact that around 80% of patients have evidence of distant metastases at the time of diagnosis. 
Evidence of locally advanced or metastatic disease preclude potentially curative surgical resection 
resulting in treatment with chemotherapy and the rapid development of resistance to all current 
therapeutics [3]. In patients with resectable tumours, the 5-year overall survival (OS) rate is still 
remarkably low at 15-20%; for non-resectable disease, it is <5%. The low OS rates in patients 
undergoing surgical resection is most likely due to undetectable distant metastases and incomplete 
removal of the tumour [4].  
 
The incidence of pancreatic cancer is highest within the 65-75-year-old age group. Current 
observations suggest that 5-10% of all cases have autosomal dominant hereditary components with 
reduced penetrance; the remainder of cases arise sporadically [5]. Some indicated risk factors are 
smoking, high alcohol intake, obesity, pancreatitis and diabetes mellitus [5-7]. The majority (65%) of 
tumours are located in the head of the pancreas, with 15% in the body, 10% in the tail and 10% within 
multiple sites (Figure 1). Patients with tumours originating in the head of the pancreas tend to present 
earlier with obstructive jaundice and pancreatitis, while patients with tumours of the tail and body 
present later and have worse prognoses [7]. 
 
Pancreatic cancer is histologically characterised into adenocarcinomas (>90%), mucinous tumours, 
neuroendocrine tumours and cystadenocarcinomas [8, 9]. The survival rates vary significantly 
depending on the histological type; the best prognosis is for patients with neuroendocrine tumours and 
the worst for patients with adenocarcinomas and mucinous tumours [9]. More than 80% of patients 
present with metastasis at the time of diagnosis, with lesions predominantly detected within the 
abdominal viscera and peritoneum [10]. The liver is a common site for metastasis due to the complete 
hepatoportal venous drainage of the pancreas [11]. Metastases originating from the body and tail of 
the pancreas can bypass lymphatic, hepatic and pulmonary filters, resulting in spread to sites 
throughout the entire body including lungs, bones and adrenal glands [10-13].  
 
Despite recent advancements in understanding the underlying molecular causes of pancreatic cancer, 
current therapeutics neither significantly prolong survival nor alleviate morbidity. Treatments are 
rarely curative outside surgical resection, with first line palliative chemotherapy remaining relatively 
unchanged since the evaluation of gemcitabine monotherapy in 1997 [14]. In 2011, it was 
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demonstrated that a combination regime of leucovorin, fluorouracil, irinotecan and oxaliplatin 
(FOLFIRINOX) generated a slight increase in survival of 4.3 months when compared to gemcitabine 
monotherapy; 11.1 and 6.8 months, respectively [15]. Unfortunately, prolonged survival came at a 
cost, with hugely increased toxicity profiles compared to gemcitabine monotherapy, including 
multiple grade 3/4 adverse events. After FDA approval in 2013, gemcitabine can now be given in 
combination with nab-paclitaxel, following reports that the combination granted prolonged survival 
compared to gemcitabine alone [16]. Although only a slight improvement (< 2 months) in survival, 
the toxicity profile was more tolerable than with FOLFIRINOX, and grade 3/4 adverse events were 
less common. 
 
Presently, clinical data indicate that both FOLFIRINOX and gemcitabine with nab-paclitaxel are 
acceptable first-line treatment options for patients with a good performance status and non-resectable 
disease [17, 18], however, a significant proportion of patients do not present with a good performance 
status and may not tolerate these combination therapies. For these patients, the only option is 
gemcitabine monotherapy [19]. 
 
The limitations of current treatments for advanced and metastatic pancreatic cancer highlight the need 
for innovative and novel therapeutics with different mechanisms of action. The dismal prognosis for 
patients afflicted with PDAC and the lack of significant improvements in survival during recent 
decades signifies that the sole use of chemotherapeutics may never be enough. This review will 
discuss the exciting therapeutic potential that oncolytic adenoviruses pose for future treatment of 
pancreatic cancer. 
 
 
Molecular alterations during the oncogenesis of pancreatic cancer 
 
Our understanding of how the combination of complex malignant transformations and precursor 
lesions ultimately develop into PDAC has significantly progressed during the last 20 years [20-22]. 
The evolution of a pancreatic ductal epithelial cell into a PDAC cell occurs in several stages: driver 
gene mutations within precursor cells followed by clonal expansion into multicellular neoplasms leads 
to the development of cellular heterogeneity and alterations in the surrounding microenvironment. 
Formation of PDAC precursor lesions is, in the majority of cases, induced via oncogenic KRAS 
activation. The two most noted precursor lesions are pancreatic intraepithelial neoplasias (PanIN) and 
intraductal papillary mucin-producing neoplasm (IPMN) [21, 23, 24]. PanINs are microscopically 
visible, non-invasive proliferations and metaplasia of once healthy ductal epithelium, and are the most 
common precursor lesions; IPMNs are grossly visible, non-invasive, mucin-producing neoplasias 
from the pancreatic ducts and branches. The progression of PanINs to dysplastic lesions occurs 
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through three distinct stages: PanIN-1, PanIN-2 and PanIN-3. A PanIN-3 lesion is described as 
carcinoma in situ within the TNM Classification for Pancreatic Cancer [25]. Cells are characterised 
by both morphological and genetic-alteration signposts for each of the PanIN stages, with only stages 
2 and 3 showing cellular dysplasia. It is important to note that PanINs will not definitely progress to 
an infiltrating PDAC, although they have the full potential to do so [26]. The genetics of pancreatic 
cancer is dominated by the presence of three to four known alterations in KRAS, CDKN2A, TP53 and 
SMAD4 [20, 22, 26, 27]. Accumulation of these somatic alterations have been identified within the 
various PanIN stages and PDAC itself (Table 1). The key mutations of pathway and regulatory 
proteins, alongside their usual functions and rate of occurrence, are outlined in Table 2. The 
consistently high prevalence of these specific genetic alterations suggests that a main evolutionary 
pathway plays a role in the development of PDAC. However, low-frequency genetic alterations have 
been recently identified, which may provide scope for a more personalised treatment with continued 
extensive research [28, 29].  
 
 
Activation of KRAS 
Mutations leading to the activation of the KRAS oncogene are already present during the early stages 
of PanIN lesions and in more than 95% of PDAC cases [22, 30, 31]. KRAS is a small GTPase 
involved in a plethora of cellular functions, including cell survival, proliferation and cytoskeleton 
remodelling. It functions as a transducer between cell surface receptors and downstream intracellular 
pathways, existing in ‘on’ and ‘off’ conformations which is conferred by binding of GTP and GDP, 
respectively [32]. The majority of mutations, including KRASG12D and KRASG12V, cause constitutive 
activation of KRAS by preventing hydrolysis of GTP to GDP [33, 34]. This locks the protein into an 
active conformation, leading to persistent stimulation of signalling pathways that drive the early 
oncogenesis of pancreatic cancer including the deregulation of cell cycle progression. The three major 
affected pathways are Raf-Mek-Erk, PI3K-Pdk1-Akt, and the Ral-guanine nucleotide exchange factor 
pathway [35, 36]. 
 
Inactivation of CDKN2A 
The human CDKN2A gene encodes the tumour suppressor genes p16INK4A and p14ARF [37]. In PDAC, 
loss of both proteins via larger gene deletions may contribute to oncogenesis by varying mechanisms, 
although evidence from humans and mice allude to p16INK4A as the primary deleterious factor. For 
example, p16 INK4A inhibits cell cycle progression at the G1/S checkpoint, which is mediated primarily 
by CDK4 and CDK6; consequently, p16INK4A loss through CDKN2A inactivation will abrogate this 
vital checkpoint enabling continuous cell cycle progression [38]. The p14ARF protein also activates the 
G1/S checkpoint, through a CDK-independent mechanism, by preventing p53-degradation [37, 39]. 
Loss of p14 ARF prevents cell cycle arrest and p53-induced apoptosis.  
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Inactivation of p53 
The p53 gene encodes the tumour suppressor transcription factor p53, which is activated in the 
presence of DNA stress or damage [40, 41]. Expression of p53 is fundamental in the regulation of 
both G1/S and G2M checkpoints, which enable DNA repair or apoptosis to occur when necessary. In 
addition, p53 increases expression of the cyclin-dependent kinase inhibitor CDKN1A, thus preventing 
cell cycle progression [42]. In pancreatic cancer, p53 is either completely inactivated by genetic 
mutations, or by alterations in the DNA binding domain, preventing p53-mediated transcriptional 
activity [20, 43]. The mutations result in continuous cell cycle progression, even in the presence of 
severe DNA damage, promoting further accumulation of genetic abnormalities in the cells [44]. 
 
Inactivation of SMAD4 
SMAD4 is a major tumour suppressor gene that is specifically altered in 45% of PDAC cases either 
through homozygous deletions (30%) or direct mutation with loss of the second gene copy (25%) [45, 
46]. SMAD4 encodes a transcription factor that acts as a crucial central mediator in the TGF-β 
signalling pathway for cellular differentiation, growth and maintenance of homeostasis [47]. During 
PanIN stages 1 and 2, the TGF-β pathway remains functional as a tumour suppressor. In contrast, 
during PanIN stage 3, SMAD4 is inactivated and the TGF-β pathway promotes growth.  
 
Induction of Epithelial to Mesenchymal Transition (EMT) 
The gain of infiltrative capacity of cancer cells via the epithelial to mesenchymal transition (EMT) is 
considered a pivotal step in the progression of primary tumours to invasive and metastatic cancer, 
including PDAC. During the process of EMT, cells undergo a developmental shift from an epithelial 
to highly motile mesenchymal or fibroblastoid phenotype; this shift facilitates invasion of malignant 
cells into surrounding tissues, the circulation and, ultimately, dissemination to distant sites [48]. EMT 
is strongly associated with decreasing expression levels of E-cadherin and increasing N-cadherin 
levels [49]. The low levels of E-cadherin result in reduced formation of adherens-junctions, thus 
leading to the loss of maintenance of the epithelial phenotype [50]. Furthermore, higher levels of N-
cadherin expression contribute to the increased invasive potential of the cells [51].   
 
 
Treatment-resistance in PDAC 
 
In addition to the late presentation of symptoms, the rapid development of resistance to chemotherapy 
remains one of the greatest barriers to curative treatments in pancreatic cancer [52]. Treatment of 
PDAC is in most cases a losing battle because of the numerous underlying genetic reprogramming 
events, including altered apoptosis, metabolic and cellular pathways, and increased EMT. In addition, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 6
acquired drug-dependent alterations such as upregulation of drug efflux pumps and deregulation of 
miRNAs counteract the effects of cytotoxic drugs [53]. Cancer cells generated from the predominant 
oncogenic drivers mentioned above may also have innate resistance to chemotherapeutic drugs [54]. 
However, many PDAC patients show some extent of gemcitabine susceptibility before the first round 
of treatment. This initial susceptibility with rapid subsequent development of resistance suggests that 
there are pre-existing resistant cell populations within the stroma or the heterogeneous tumour itself, 
with the initial treatment selecting for these resistant populations [55]. For example, elimination of 
gemcitabine-sensitive cell populations enables resistant cell populations to expand and repopulate the 
tumour microenvironment within weeks of treatment [54].  
 
Interestingly, the tumour microenvironment has been increasingly recognised as a major contributor 
to the development of chemoresistance in pancreatic cancer [56-58]. Desmoplasia is a well-
established characteristic of PDAC that involves a fibro-inflammatory process leading to cancer-
associated fibrosis of the stroma which restricts access of chemodrugs. The desmoplastic stroma is 
comprised of both cellular and non-cellular components, with the main constituents being non-
quiescent pancreatic stellate cells (PSCs), immune cells, endothelial cells and fibroblasts, that 
promote tumour growth [59]. Activated PSCs are known to be the main regulators of pancreatic 
cancer-associated desmoplasia, and may promote further progression and metastasis [60, 61]. The 
non-cellular component is comprised of an extracellular matrix (ECM), which contains proteins, 
glycosaminoglycans and proteoglycans, forming the architectural foundations for cancer growth and 
maintenance. A key glycosaminoglycan, hyaluronic acid, is markedly overexpressed in PDAC, 
making it a structural hallmark and potential therapeutic target of the pancreatic cancer stroma [62]. In 
summary, the roles of the microenvironment in the development of chemoresistance are: i) 
Dysfunctional vasculature resulting in raised stromal interstitial pressure that prevents sufficient 
deposition of drugs within the tumour. ii) Stromal cells promote resistance by generation of the 
desmoplastic microenvironment, promoting EMT and, therefore, metastasis. iii) Components of the 
ECM promote chemoresistance by affecting gene expression in cancer cells. 
 
It is clear that the resistance to cytotoxic drugs in PDAC cannot be conquered by currently available 
anti-cancer drugs but could, however, be combatted by directly altering the genetic landscape of the 
cancer cells. Oncolytic adenoviral mutants may pave the way as genetic vectors, supplying the cancer 
cells with new ways of dying with no or limited toxicity to healthy cells.   
 
 
Oncolytic Adenoviruses 
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Adenoviruses are small non-enveloped double-stranded DNA viruses with a 30-38 kb linear double-
stranded genome (Figure 2) [63]. The family includes >57 serotypes that are classified in subtypes A-
G, based on their respective agglutination properties. Adenovirus-infection is facilitated by binding of 
viral fibre-proteins to the epithelial-specific cellular Coxsackie virus and Adenovirus Receptor 
(CAR), followed by internalisation through viral penton-binding to integrins; mainly αvß3 and αvß5 
(Figure 2). Once internalised, the viral protein coat is degraded, and the genome is transported to the 
host cell nucleus for transcription. The first step in the viral life-cycle is expression of the early viral 
E1A proteins, required for initiation of S-phase that is fundamental for viral propagation [63]. The 
E1ACR2 domain in the E1A protein binds to the retinoblastoma protein (pRb), which in turn releases 
E2F and forces the infected cell to enter S-phase. Following E1A translation and S-phase entry, 
expression of the viral anti-apoptotic E1B55K and E1B19K proteins protect the infected cells from 
premature death by inhibiting the G1/S checkpoint and inactivating both p53 and mitochondrial 
depolarisation. In addition, the viral E3- and E4-genes protect the infected cell from immune-
mediated cell killing and prevent activation of DNA-damage repair, respectively.  
 
To date, multiple oncolytic viruses have been generated, with the majority based on genomic 
alterations of serotype 5 species C (Ad5) [64-66]. The advantages of Ad5-based mutants include the 
ease of genetic engineering of the small genome with all gene functions established; high-titre 
production under good manufacturing production (GMP); and specific targeting of both dividing and 
non-dividing epithelial cells, including adenocarcinomas. Furthermore, even the wild type Ad5 virus 
causes only mild upper respiratory tract infections that resolve spontaneously in otherwise healthy and 
immunocompetent individuals [67]. Extensive data from clinical trials using replication-selective 
oncolytic Ad5-based mutants have proved that these mutants are safe in cancer patients and 
specifically eliminate tumour cells with limited toxicity to healthy cells [64, 68-72]. 
 
 
Viral activation of the anti-tumour immune response 
 
In contrast to current chemotherapeutic and targeted anticancer drugs, oncolytic adenoviruses act 
through multiple mechanisms to eliminate cancer cells and prevent recurrence. In addition to local 
amplification of viral dose within the tumour microenvironment and activation/inhibition of numerous 
cellular pathways, adenoviruses also activate the host anti-tumour immune responses [65, 73, 74]. 
Generation of a potent immune response is critical for maximum therapeutic efficacy in response to 
oncolytic viruses.  
  
One of the emerging hallmarks of cancer is the ability to evade the host immune system and, thus, 
avoid immunologically-mediated destruction [75]. During the process of early immune editing, cancer 
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cells that present tumour antigens are highly susceptible to detection and removal by the immune 
system, resulting in a selection-based elimination [76]. Following immune destruction of the initial 
immunogenic cancer cells, continued aberrant cell division of the remaining populations results in 
accumulation of mutations and reduction in cancer-cell immunogenicity. Eventually, the tumour will 
fully escape recognition by the immune system [76, 77]. The main mechanisms underlying tumour 
evasion are defective tumour-associated antigen presentation and over-production of immune-
suppressive factors [78]. Adenovirus-induced cancer cell lysis causes activation of the innate immune 
defence and exposure of novel tumour antigens that facilitates the generation of an anti-tumour 
immune response that counteracts the immune suppressive tumour microenvironment. Importantly, 
adenoviral infection induces immunogenic cell death (ICD) through direct cell lysis and release of 
tumour-associated antigens (TAAs), as well as damage- and pathogen-associated molecular pattern 
molecules (DAMPs and PAMPs) [73, 74, 79, 80]. Activation of the adaptive immune responses 
occurs after presentation of these molecules, particularly DAMPs, to antigen-presenting cells (APCs) 
such as the dendritic cell (DC) [81, 82]. Activated DCs migrate to draining lymph nodes for cross-
presentation to CD8+ T-cells, the primary anti-tumour effector cells [83]. DCs also activate CD4+ T-
helper cells, which are fundamental for the development of long-term anti-tumour immunity [84]. 
Viral infection induces the release of pro-inflammatory cytokines and chemokines from both 
infiltrating and resident immune cells as well as from the infected cells. As a result, this localised 
inflammation may augment the function of infiltrating lymphocytes while contributing towards the 
generation of anti-tumour immunity [84]. Therefore, oncolytic adenoviruses may play a potential role 
in reversing the profound immunosuppressed state of the PDAC microenvironment, which ordinarily 
prevents the successful infiltration/activation of CD4+ and CD8+ T-cells and release of anti-tumour 
chemokines and cytokines [85]. In addition, adenoviruses are often armed with therapeutic transgenes 
that promote local cytokine-activation to exploit inflammatory-induced infiltration of lymphocytes, 
including IL-12, IL-18 and IFN-α that stimulate both innate and adaptive immune responses [73, 86-
88]. 
 
Clinical trials with oncolytic adenoviruses may be the only current way of demonstrating the 
induction of potent long-term anti-tumour immunity in response to adenoviral infection due to the 
limitations with preclinical in vivo models. The species-specificity of adenovirus precludes the 
generation of relevant immune mechanisms in other species in response to potent viral replication and 
cell lysis; as a result, murine models are inadequate for investigating these anti-tumour immune 
responses.    
 
 
Generation of PDAC-selective potent oncolytic adenoviral mutants  
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The first oncolytic adenoviruses were developed via the deletion of viral genes, the so-called 
complementation deletions, which are fundamental for viral replication within normal cells but not in 
cancer cells due to their altered cell cycle and apoptosis pathways. The first oncolytic adenovirus to 
be evaluated in cancer patients, including PDAC patients, was Onyx-015 (dl1520) with the anti-
apoptotic E1B55K-gene deleted (Figure 2) [71, 89, 90]. The E1B55K protein binds and inactivates 
p53, which is already non-functional in the majority of cancers including pancreatic cancer. Thus, 
Onyx-015 propagation could proceed in cancer cells but not in normal cells with functional p53. In 
the initial Phase I trial targeting patients with unresectable, locally advanced pancreatic cancer, Onyx-
015 was delivered directly into the tumours by CT-guided or intraoperative administration [89]. While 
safety was clearly demonstrated, no significant responses were reported. In a follow-up Phase I/II 
trial, the virus was delivered intra-tumourally by ultrasound-guided administration in combination 
with intravenous gemcitabine [68]. Despite improved efficacy compared to each agent alone (partial 
regression, 2/21; minor responses, 2/21), the overall outcomes were disappointing and no further trials 
in PDAC patients were undertaken with Onyx-015. The poor efficacy of Onyx-015 was attributed to 
the lack of viral mRNA nuclear export, a function mediated by E1B55K in addition to p53 
inactivation, that was later demonstrated to be essential for viral replication [70, 91]. Without a 
functional E1B55K-protein, viral replication and spread within the tumour were severely attenuated. 
Furthermore, the deletion of the immune-regulatory E3B-genes, that had been included for safety 
reasons, contributed to premature elimination of virus-infected cells by the host macrophages prior to 
maximal viral replication [92].  
 
To date, several oncolytic adenoviral deletion-mutants have been developed with highly specific 
genetic alterations and retained activity, resulting in promising improvements in efficacy within both 
preclinical studies and early-phase clinical trials with PDAC patients (Table 3).  The most common 
alteration is deletion of the pRb-binding E1ACR2-region, generating mutants with proven efficacy in 
the majority of cancers, including pancreatic cancer. Deletion of the E1ACR2-domain prevents viral 
replication in normal cells while propagation readily proceeds in cancer cells with deregulated cell 
cycle, such as in PDAC cells with activating KRAS mutations. Mutants with the E1ACR2-deletion 
include dl922-947 [93], Ad∆24RGD [94], Ad∆∆ and Ad5-3∆-A20T [95, 96], and have been 
demonstrated to potently replicate and spread within PDAC cell models in both in vitro and in vivo 
preclinical studies.  Additional modifications include insertion of E2F-binding domains to drive viral 
replication (e.g. VCN-01 and LOAd703) and transgene expression to activate the host anti-tumour 
immune responses (e.g. LOAd703 and Ad5-yCD/mutTKSR39rep-hIL12), which will be discussed 
below.  
 
 
Clinical trials targeting pancreatic cancer with adenoviral mutants 
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Despite the poor efficacy of Onyx-015, the trials convincingly demonstrated feasibility, tolerance and 
safety of adenoviral delivery, paving the way for future clinical evaluation with improved oncolytic 
viruses. Interestingly, the Chinese FDA (SFDA) approved the clinical application of an almost 
identical mutant, H101 (E1B55K- and E3B-deleted) for head and neck cancers in combination with 
cisplatin and/or 5-fluorouracil (5-FU) in 2005 [97, 98]. Currently, thousands of patients have been 
treated with H101 with no reported side-effects. To date, there are a great number of published 
clinical trials involving PDAC patients that utilise modified adenoviral mutants, both replicating and 
non-replicating (outlined in Table 3).  
Currently, patients are being recruited in two phase I trials aimed at evaluating mutants based on the 
Onyx-015 backbone with additional modifications, which were reported to improve efficacy in 
preclinical studies; Ad5-yCD/mutTK(sr39)rep-ADP and Ad5-yCD/mutTK(sr39)rep-IL12 [99, 100]. 
Both mutants express the chimeric prodrug converting enzyme yeast cytosine deaminase 
(yCD)/mutant sr39 herpes simplex virus thymidine kinase (yCD/mutTKsr39) that potently converts 
the prodrugs 5-FC and ganciclovir to their respective metabolites 5-fluorouracil (5-FU) and 
ganciclovir-5-monophosphate (ganciclovir-MP). Enzyme expression is regulated by the CMV-
promoter that also controls expression of the Adenoviral Death Protein (ADP) or IL-12 to further 
boost anti-tumour activity in PDAC patients. In contrast, the replicating AdVince virus targets liver 
metastases originating from pancreatic neuroendocrine tumours (NET) [101]. Although, pancreatic 
cancer is dominated by adenocarcinomas (PDAC), approximately 10% of the pancreatic patient 
population suffer from metastatic NETs, creating a distinct group in need of a novel therapeutic 
option. NETs typically produce the secretory protein chromogranin A (CgA), which presents the 
opportunity to exclusively target viral replication to NET cells. In AdVince, E1A expression is 
controlled by the CgA-promoter region and to minimise hepatocyte toxicity, target sequences for the 
hepatocyte-specific microRNA miR122 were incorporated into the 3’-untranslated region of the E1A 
gene to prevent viral replication in hepatocytes [101]. In order to enhance the transduction of tumour 
cells, the protein transduction domain (PTD) from the Trans-Activator of Transcription (Tat) protein 
of human immunodeficiency virus (HIV)-1 was inserted into the hypervariable region (HVR)-5 of the 
viral hexon protein. This PTD insertion achieves a CAR-independent route of infection and 
dissemination throughout the NETs. Although only tested pre-clinically on surgically-resected 
metastatic NETs originating from the small intestine, AdVince displayed NET-cell specificity with 
high lytic activity, as well as limited toxicity in isolated human hepatocytes compared to wild-type 
virus. AdVince is currently being evaluated in a phase I/IIa clinical trial for patients with multiple 
metastatic liver lesions of pancreatic NET origin. Importantly, CgA is expressed in healthy tissues 
including pancreatic β-cells, the pituitary gland, and adrenal medulla [101] and is therefore 
administered in close proximity to the target tumours via intrahepatic artery infusion. 
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Interestingly, a number of trials are currently evaluating non-replicating adenoviral mutants that 
cannot spread within the tumour and require expression of prodrug converting enzymes or cytotoxic 
factors to induce tumour cell killing (Table 3). By definition, non-replicating mutants have the viral 
E1A-gene deleted that prevents replication in any cell. In AdV-tk, the immunoregulatory E3-genes 
were deleted in addition to E1A to enable insertion of the HSV-tk enzyme expressed from the CMV-
enhancer/promoter [102, 103]. Favourable responses were reported in a Phase I trial after intra-
tumoural injections. In the TNFerade mutant, the entire E1-gene (E1A and E1B) was deleted in 
addition to the E4-genes and a partial E3-deletion to enable insertion of TNFα regulated by the 
radiation activated early growth response element (Egr-1) [104]. TNFerade was reported to be safe 
but had no significant advantage compared to current standard of care in a small randomised 
PhaseII/III trial. ETBX-011 was deleted in the E1-genes (E1A and E1B), the E2B- (the viral 
polymerase) and the E3-genes [105, 106]. The rationale for deleting the major early viral genes was to 
enable insertion of the tumour associated carcinoembryonic antigen (CEA) regulated by the CMV 
promoter. Potent expression of CEA elicited anti-tumour activity as a result of cell-mediated 
immunological responses. Furthermore, CEA was modified to contain the highly immunogenic 
epitope, CAP-1-6D. Promising preclinical results were reported [105], which explains why multiple 
phase I/II trials with ETBX-011 in PDAC patients are currently underway (outlined in Table 3). 
 
To date, the most promising results for treatment of PDAC, have been reported for the replication-
selective mutants LOAd703 and VCN-01, and these mutants will be discussed in detail below.  
 
LOAd703 
Deletion of the E1ACR2-region has been established to produce highly tumour-selective and 
efficacious oncolytic adenoviral mutants and was therefore included in LOAd703. In addition, E2F-
binding sites were inserted upstream of E1A to control its expression and viral replication, and the 
immune regulatory E36.7K and E3gp19K genes were deleted for increased immunogenicity [107-
109]. The novelty in LOAd703 is the insertion of a trimerized, membrane-bound human CD40 ligand 
(TMZ-CD40L) and the full-length human 4-1BB ligand (4-1BBL), both under control of the CMV 
promoter.  
 
CD40 belongs to the tumour necrosis factor receptor (TNFR) family and is expressed by B-cells, 
professional antigen presenting cells (APCs), non-immune cells and tumour cells [110]. The ligand, 
CD40L (a.k.a. CD154) is expressed primarily by activated T-cells and B-cells, and by natural killer 
cells (NK), mast cells, monocytes and basophils[110]. CD40/CD40L interactions play pivotal roles in 
governing humoral and cell-mediated immunity, particularly for ‘licensing’ DCs to undergo 
maturation and effectively trigger cytotoxic T-cell activation/differentiation[110-112]. It was 
hypothesised that CD40/CD40L interactions in PDAC may provide a key regulatory step in the 
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generation of a T-cell-dependent anti-tumour immune response [113] by mechanisms including 
activation of the adaptive immune system and CD40-mediated apoptosis of cancer cells [108]. 
However, this hypothesis was contested when analysing data from a clinical trial evaluating a CD40-
activating monoclonal antibody (mAB) in combination with gemcitabine in PDAC patients, resulting 
in partial responses in primary and metastatic lesions; analysis of tumour biopsies revealed infiltration 
by macrophages rather than T-cells [113]. Nonetheless, there is evidence that therapies involving 
CD40 agonists may produce an anti-tumour immune response via myeloid-cell activation, albeit 
potentially without T-cell involvement due to poor tumour infiltration.[108] The TMZ-CD40L in 
LOAd703 may increase myeloid and T-cell infiltration of PDAC tumours, and promote lymphocyte 
transmigration across CD40L-stimulated endothelial cells [108].  
 
The 4-1BB protein is also a member of the TNFR family and is typically expressed on activated T-
cells and natural killer cells, monocytes, neutrophils and macrophages [114]. Its natural ligand, 4-
1BBL (a.k.a. CD137L), is expressed on B-cells, activated T-cells, dendritic cells and macrophages 
[115]. Binding of 4-1BBL to 4-1BB is associated with the expansion of innate immune cells, 
including NK cells, and potentiation of immunological memory [116, 117]. In one study, cultured 
surgical PDAC specimens were treated with an activating 4-1BB mAb, resulting in increased numbers 
of tumour-infiltration lymphocytes (TIL) [118]. The 4-1BBL in LOAd703 may potentiate the 
infiltration of lymphocytes into the tumour and increase the efficacy of CD40/CD40L orchestrated 
anti-tumour immune responses. 
 
Pre-clinical studies using LOAd703 demonstrated that the mutant successfully replicated and lysed 
cultured human PDAC cells (Panc01, BxPc3, MiaPaca2, PaCa3) and subcutaneous Panc01 xenografts 
in immune deficient mice [107]. In these models, intratumoural administration of LOAd703 in 
combination with gemcitabine significantly reduced tumour growth compared to single agent 
treatments. Due to the lack of immune competent murine models, further evaluation was conducted in 
isolated human immune cells and infected DCs, which led to NK cell expansions in response to the  
replication-independent expression of TMZ-CD40L and 4-1BBL, resulting in cytokine production 
[108]. Due to the poor infiltrative capacity of leukocytes into the desmoplastic stroma in PDAC 
tumours, viral replication and upregulation of cytokines may aid in producing a significant anti-
tumour immune response in patients. Safety and preliminary anti-tumour activity of LOAd703 is 
currently being evaluated in Phase I/II and I/IIa trials including PDAC patients with unresectable 
cancers (Table 3). Patients in the phase I/II trial will receive eight intratumoural LOAd703 injections 
in combination with gemcitabine and/or nab-paclitaxel; in the phase I/IIa trial, six intratumoral 
LOAd703 injections every other week together will be performed alongside standard of care (SOC) 
gemcitabine and nab-paclitaxel. 
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VCN-01 
Replication-selectivity of VCN-01 was achieved via deletion of the E1ACR2-region and insertion of 
E2F-binding sites to control E1A-expression and viral replication [119, 120]. To circumvent 
adenoviral hepatocyte transduction, the heparin sulfate glycosaminoglycans (HSG) putative-binding 
site KKTK in the fibre shaft was replaced by an RGD-motif [121, 122].  This KKTK→RGDK 
mutation decreased liver transduction in murine models after intravenous injection and increased 
tumour-targeting [123, 124]. VCN-01 penetrates the dense desmoplastic stroma in PDAC tumours 
because of incorporation of the human glycosylphosphatidylinositol-anchored enzyme PH20 
hyaluronidase in the viral genome, which breaks down the ECM [120]. Currently, two phase I trials 
are underway including PDAC patients with unresectable cancers (Table 3). The use of the anchored 
PH20 hyaluronidase should theoretically allow for greater adenoviral dissemination throughout the 
desmoplastic stroma and ECM, facilitating both viral spread and immune cell infiltration. In one trial, 
three intratumoral injections of VCN-01 every 28 days in combination with intravenous Gemcitabine 
and Abraxane® is assessed, while in the second trial, a single intravenous injection of VCN-01 in 
combination with intravenous Gemcitabine and Abraxane® is evaluated. 
 
 
Challenges with systemic delivery of adenoviral mutants in PDAC patients 
 
In the vast majority of clinical trials with oncolytic adenoviruses the mutants have been administered 
intra-tumorally. Unless potent anti-tumour immune responses are initiated, many of the current 
mutants are not suitable for the 80% of patients that present with already active metastatic disease 
because of the inability to reach distant tumour lesions in sufficiently high doses after systemic 
delivery [125]. The ultimate aim is to generate mutants that have prolonged half-life in blood and can 
reach and eliminate all tumour lesions after systemic delivery, and concurrently activate anti-tumour 
innate and adaptive immune responses. The barriers for successful systemic delivery will be discussed 
below. 
 
Pre-existing antibodies neutralise Ad5 
One challenge with systemic delivery is the presence of pre-existing humoral immunity. Anti-Ad5 
neutralising antibodies (NABs) are detectable in up to 85% of the population indicating prior 
exposure to Ad5 at some point in their lives [126]. For the remaining few lacking acquired immunity, 
primary exposure to Ad5 will initiate innate and adaptive immune responses, rendering the individual 
immune to future administrations within two weeks [127]. One strategy to evade NABs is the 
chemical conjugation of polymers such as N-(2-hydroxypropyl)methacrylamide (HPMA) or 
polyethyleneglycol (PEG) to the viral capsid. However, it was reported that viral infectivity was 
decreased and a strong humoral immune response still occurred suggesting that shielding may be 
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more of a hindrance than a benefit [127-129]. Recent work using an albumin-binding strategy 
protected adenoviruses from NABs and reduced blood clearance in mice [130]. An albumin-binding 
domain (ABD) was inserted in the HVR1 region of the hexon protein, thus allowing viral binding to 
albumin, which prevented binding by NABs. However, in vitro studies demonstrated that infectivity 
of adenoviruses with the inserted ABD was decreased in the presence of human serum albumin. This 
method may be of future interest when used in combination with tumour targeting modifications.  
 
Non-tumour uptake of Ad5 
The predominant sites for Ad5 uptake after systemic delivery are liver hepatocytes and the hepatic 
reticuloendothelial system, which is composed of resident macrophages called Kupffer cells (KC), 
and liver sinusoidal endothelial cells (LSEC). KCs are responsible for sequestration of up to 90% of 
intravenously administered Ad5 within minutes, posing a monumental barrier to systemic delivery 
[131, 132]. Ad5 uptake by KCs is independent of CAR but may involve αvβ5-integrins [122, 133, 
134]. Ad5 also binds heparan sulphate glucosaminoglycans (HSPG), expressed on cell membranes, 
via a KKTK motif in the viral fibre shaft and mediates binding to numerous tissues including hepatic 
cells. By substituting the four amino acid KKTK domain with the integrin binding sequence RGDK in 
the VCN-01 mutant, systemic delivery to tumours was reported to be more efficient, ablating HSPG 
binding. Although, hepatocyte uptake and KC elimination were not prevented [123][[124].  A family 
of receptors known as scavenger receptors (SR) have been shown to facilitate KC-mediated uptake of 
Ad5, with SRA-II involved in the in vitro uptake through the hexon hypervariable regions (HVR) 1, 
2, 5 and 7 [132]. PEGylation of the HVRs prevented KC uptake, with a subsequent 20-fold increase in 
hepatocyte transduction. Furthermore, depletion of platelets with either anti-CD42b, neuraminidase or 
anti-CD41, suggested that KC-uptake was platelet-independent contesting a previous hypothesis that 
platelets assist the sequestration [135, 136]. In vivo studies demonstrated an increase in adenoviral 
transduction of hepatocytes in the presence of the vitamin K-dependent coagulation factors VII, IX, X 
and protein C [137, 138]. Factor X binding to Ad5 HVR 5 and 7 promotes KC uptake and fibre knob 
binding to FIX/complement-4 binding protein (C4BP) increases hepatocyte uptake.  However, it was 
reported that in mice, these coagulation factors were only required for hepatocyte-uptake but not for 
KC-uptake [135]. Additionally, pre-existing IgM antibodies neutralise Ad5, with opsonisation 
orchestrated via the co-interaction with various complement components including complement 
receptor 3 (CR-3) or the Fc receptor, that facilitate subsequent KC-uptake [132, 135, 139].  
The reticuloendothelial system has been evaded by different strategies including pre-administration of 
virus to saturate receptors and uptake mechanisms [127, 140]; modification of the virus (e.g. HVR 
PEGylation) [127, 132]; and by detargeting and retargeting of the fibre (e.g. KKTK to RGDK 
mutation) [123]. Saturation of KCs with an oncolytic adenovirus in pre-clinical in vivo models 
increased the anti-tumour responses after a subsequent single intravenous injection of the same virus 
[141]. When KC saturation was combined with warfarin pre-treatment, hepatotoxicity was reduced, 
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and anti-tumour efficacy enhanced. These findings indicate that a two-pronged attack is superior in 
order to prevent both reticuloendothelial sequestration and hepatic parenchyma uptake when 
delivering adenoviruses systemically. 
 
Erythrocyte binding 
Ad5 binds with high affinity to human erythrocytes via both CAR and complement receptor-1 (CR1), 
but is not internalised [142]. Thus, the erythrocytes act as a viral sink, dramatically reducing the levels 
of free circulating virus and the bioavailability. A strategy to partly overcome this is polymer 
‘stealthing’, for example, by using a new generation of an epidermal growth factor (EGF)-targeted, 
positively charged, HPMA polymer (EGF-P) [142]. However, early data from an ongoing clinical trial 
of ICOVIR-5 (NCT01864759), suggests that erythrocyte-binding may not pose a major obstacle to 
systemic viral delivery and that focus should be diverted to other major obstacles [143]. Murine 
erythrocytes do not express CAR which means that, as a consequence, murine models are not 
representative of the situation in humans after systemic delivery of Ad5-mutants when assessing the 
erythrocyte viral sink [144].  
 
To move towards systemically deliverable oncolytic adenoviruses for targeting of metastatic PDAC, 
strategies to overcome the hepatic and blood factor barriers need to be developed for example by 
combining coat modifications, de- and re-targeting, and chimeric serotypes with different receptor and 
binding preferences.  
 
Promising Developments 
 
We recently developed a novel adenoviral mutant with multiple gene alterations to target PDAC 
through systemic administration (Ad5-3∆-A20T) [96]. The mutant was generated from Ad∆∆, which 
is tumour selective because of the E1ACR2-deletion, and enhances chemodrug-induced apoptosis 
through deletion of the viral anti-apoptotic Bcl-2 functional homologue E1B19K [95, 145-147]. The 
absence of a functional anti-apoptotic E1B19K-gene allowed for greater pancreatic cancer cell death 
through enhancement of drug-induced apoptosis and synergistic cell killing in combination with 
chemotherapeutics [95, 146, 148, 149]. In pre-clinical studies, the E1B19K-gene-deleted mutants 
potently synergised with apoptosis-inducing cytotoxic drugs including gemcitabine, which allows for 
highly efficient tumour elimination while utilising significantly lower doses of chemotherapeutics. 
The double-deletion of E1ACR2 and E1B19K has the greatest synergistic effects on cancer cell 
killing and is significantly more potent than wild type Ad5. Additionally, in Ad5-3∆-A20T, the 
E3gp19K-gene is deleted to promote MHC class I expression on the infected cancer cells and promote 
reactivation of the host anti-tumour immune responses [96]. Furthermore, Ad5-3∆-A20T is targeted to 
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αvß6-integrins that are frequently expressed by PDAC tumours but not by healthy tissues [150]. 
Additional fibre-modifications improved specific uptake in tumour cells by reducing blood-factor 
binding and improved the tumour-to-liver viral genome ratios in murine models [140, 142, 151]. 
These preclinical findings suggest that Ad5-3∆-A20T may be suitable for clinical translation targeting 
late stage PDAC lesions in combination with current standard of care. Additional preclinical toxicity 
and efficacy studies are underway. However, translation of any promising oncolytic viral mutant from 
preclinical studies to the clinic is considerably hampered by the limitations of in vivo models. Human 
adenoviruses do not replicate and spread within the murine components of xenografted human tumour 
cells. Furthermore, the absence of an adaptive immune system within these models prevents 
exploration of relevant cytokines, immune cells and development of long-term immunity.  
Currently, several in vitro model systems have been explored to bridge the gap that currently exists 
between cells grown on plastic or xenografted into immune-deficient mice and clinical translation. 
Promising developments involve PDAC cells co-cultured with various stromal cells including 
activated stellate cells in 3-dimensional (3D) collagen/Matrigels (e.g. organotypic models) [152, 153] 
and in organoids (without supporting gels) [154, 155].  In the organotypic 3D models, PDAC cells 
invaded the gels only in the presence of activated stellate cells (non-transformed PS1 cells), 
mimicking tumour invasion in patients [153, 156]. Importantly, it was demonstrated that Ad5, Ad∆∆ 
and the novel mutant Ad5-3∆-A20T infected and spread within the 3D structures. Furthermore, they 
potently eliminated PDAC cells and also infected the activated PS1 cells that likely contributed to the 
higher cell killing efficiency compared to monocultures of PDAC cells [96]. Interestingly, PDAC and 
PS1 cells grown in organotypic cultures have been co-cultured with isolated human immune cells to 
study migration and interactions with T-cells and macrophages [157]. Further optimisation of these 
organotypic or organoid cultures may enable more accurate predictions of viral interactions with host 
immune factors within the human tumour microenvironment and better predict which viral mutant 
should be pursued for clinical development.  
 
 
Concluding remarks 
 
Oncolytic adenoviruses are at the forefront of clinical utilisation, however, the future success of 
providing systemically-delivered therapy for pancreatic cancer depends hugely on the strategies used 
to overcome a plethora of limitations. Achieving sufficient bioavailable doses of adenovirus after 
intravenous injection in an immune-competent host will likely be a major challenge that may require a 
combination of strategies such as those describe for Ad5-3∆-A20T, VCN-01 and LOAd703. Arming 
the viruses with immune stimulatory factors and cytotoxic transgenes is the most promising way 
forward to target both early- and late-stage cancers, and with additional capsid-modifications these 
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mutants may also be delivered systemically to distant metastasis. Although the number of novel 
mutants currently entering clinical trials for pancreatic cancer is a monumental achievement, the vast 
majority of trials still fail to target metastatic lesions that are present in 80% of patients at the initial 
treatment. However, the burst of novel mutants that are clinically evaluated is exciting as they will 
provide fundamental information that cannot currently be obtained in pre-clinical studies. Results on 
efficacy and the effects of viral replication on the host anti-tumour immune responses and 
development of tumour immunity are eagerly awaited from these trials. 
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Table 1: The morphological features and key driver gene alterations from normal 
pancreas, through the various PanIN stages to PDAC. 
 
 
 
 
 
 
 
 
 
 
 
  
Stage Morphological Features Key Cumulative Driver Gene 
Alterations at Various Stages 
Refs 
Normal Cuboidal epithelium with ducts; 
islet cells with surrounding acinar 
tissue. 
None [22, 
158]  
PanIN-1 Columnar or cuboidal cells which 
are flat or papillary. Cells have 
complete nuclear polarity and no 
nuclear atypia. 
 
[22, 
158, 
159]  
PanIN-2 Multiple nuclear abnormalities: 
pleomorphism; hyperchromasia; 
loss of polarity; crowding; and 
nuclear pseudostratification. 
 
[22, 
158, 
159]  
PanIN-3 Widespread loss of nuclear polarity; 
marked atypia of nuclei; and 
prevalent mitosis within the 
basement membrane. 
 
[22, 
158, 
159] 
PDAC Similar to PanIN-3 but with 
infiltration through the basement 
membrane. Neoplastic glands 
undergo perineural and vascular 
invasion in a completely haphazard 
manner. 
 
[158, 
160] 
KRAS activation 
CDKN2A inactivation 
Inactivation of  
TP53 and SMAD4 
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Table 2: The proportions and downstream consequences of the key PanIN stage and 
PDAC gene alterations. 
 
Usual protein function from: [161]  Downstream consequences from: [20]   
Proportion of tumours data from: [30] 
  
Pathway 
or 
Regulatory 
Process 
PanIN 
Driver 
Gene 
Alterations 
Protein 
Function 
Downstream 
Consequences of 
Genetic 
Alteration 
Proportion 
of 
Tumours 
with 
PanIN 
Driver 
Gene 
Alterations 
Refs 
KRAS 
Signalling 
KRAS 
activation 
Oncogene; 
GTPase; 
activation of 
MAPK activity. 
Growth 
independent of 
ligand-bound 
RTK. 
Immunosupression 
Metabolic 
reprogramming 
Protein 
scavenging 
95% [20, 30, 
161] 
TGF-β 
Signalling 
TGFΒR2 
inactivation 
 
 
SMAD4 
inactivation 
Transforming 
growth factor- 
β receptor type 
II; regulation of 
growth. 
 
Mothers against 
decapentaplegic 
homologue 4; 
BMP signalling 
pathway. 
Loss of 
homeostatic 
mechanisms. 
 
 
 
Loss of gene 
expression that is 
co-regulated by 
p53 and TGF- β 
5 - 10% 
 
 
 
55% 
[20, 30, 
161] 
G1/S 
Phase 
Transition 
Regulation 
CDKN2A 
inactivation 
Cyclin-
dependent 
kinase inhibitor 
2A; G1/S 
transition of 
mitotic cell 
cycle; tumour 
suppressor. 
Loss of G1/S 
checkpoint. 
90% [20, 30, 
161] 
DNA 
Damage 
Control 
TP53 gain 
of function 
Tumour 
suppressor p53; 
DNA damage 
response. 
Loss of G1/S and 
G2/M 
checkpoints. 
 
Resistance to 
apoptotic 
signalling. 
80 - 85% [20, 30, 
161] 
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Table 3: Pancreatic cancer clinical trials with adenoviral mutants. 
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Adenovirus  
Mutant 
 
Genetic 
Modifications 
Trial 
Phase; 
Number 
of Patients 
Route of 
Administrati
on  
Trial Outcomes  Ref 
ONYX-015 
(dl1520) 
E1B55K- and E3B-
deleted. 
Phase I; 23 Intratumoral 
injection via 
CT-guided or 
intraoperative 
injection. 
Feasible and well-
tolerated. Viral 
replication was not 
detectable. 6/23 minor 
responses; 11/23 stable 
disease; 5/23 
progressive disease. 
[162] 
[89] 
ONYX-015 
(dl1520) 
E1B55K- and E3B-
deleted. 
Phase I/II; 
21  
Intratumoral 
injection via 
endoscopic 
ultrasound 
guidance. 
Feasible and generally 
well-tolerated. 
2/21 minor responses; 
6/21 stable disease; 
2/21 partial regression; 
11/21 progressive 
disease or dropped out 
of study. 
[162] 
[68] 
Ad5-
yCD/mutTK
SR39rep-ADP 
E1B55K-deleted; 
expression of 
chimeric 
yCD/mutTKSR39 and 
the 11.6K (ADP) 
genes regulated by 
the CMV promoter. 
Phase I; 8 Endoscopic 
ultrasound 
guided 
intratumoral 
injection. 
Terminated due to poor 
enrolment. 
[99, 
163] 
Theragene®
, Ad5-
yCD/mutTK
SR39rep-ADP 
E1B55K-deleted; 
expression of 
chimeric 
yCD/mutTKSR39 and 
the 11.6K (ADP) 
genes regulated by 
the CMV promoter.  
Phase I; 9 Endoscopic 
ultrasound 
guided 
intratumoral 
injection. 
Currently recruiting 
patients. 
[99, 
164] 
Ad5-
yCD/mutTK
SR39rep-
hIL12 
E1B55K-deleted; 
expression of 
chimeric 
yCD/mutTKSR39 and 
single-chain murine 
IL-12 genes in E3-
region under control 
of the CMV 
promoter. 
Phase I; 9 Endoscopic 
ultrasound 
guided 
intratumoral 
injection. 
Currently recruiting 
patients. 
[100, 
165] 
AdVince Human 
chromogranin A 
promoter driving 
E1A expression in 
neuroendocrine 
cells; miR122 target 
sequences to reduce 
liver toxicity; 
expression of cell-
penetrating peptide 
in capsid. 
Phase I/IIa; 
35 
Intrahepatic 
artery 
infusion. 
Currently recruiting 
patients. 
[101, 
166] 
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LOAd703 E1ACR2-, 
E3gp19K- and 
E36.7K-deleted; 
expression of TMZ-
CD40L and 4-1BBL 
under control of the 
CMV promoter. 
Phase I/IIa; 
26 
Image-guided 
intratumoral 
injection. 
Currently recruiting 
patients. 
[107, 
108, 
119, 
167, 
168] 
LOAd703 E1ACR2-, 
E3gp19K- and 
E36.7K-deleted; 
expression of TMZ-
CD40L and 4-1BBL 
under control of the 
CMV promoter. 
Phase I/II; 
50 
Image-guided 
intratumoral 
injection. 
Not yet open for patient 
recruitment. 
[107, 
108, 
119, 
167, 
169] 
VCN-01 E1ACR2-deleted; 
E1A expression 
regulated by 8x E2F- 
and 1x Sp1-binding 
sites; expression of 
human 
hyaluronidase; and 
retargeted by RGDK 
insertion in the fibre 
knob. 
Phase I; 18 Intratumoral 
injection. 
Ongoing. [170, 
171] 
VCN-01 E1ACR2-deleted; 
E1A expression 
regulated by 8x E2F- 
and 1x Sp1-binding 
sites; expression of 
human 
hyaluronidase; and 
retargeted by RGDK 
insertion in the fibre 
knob. 
Phase I; 36 Intravenous 
injection. 
Currently recruiting 
patients. 
[170, 
172] 
TNFerade
™ 
E1A-, E1B- and E4-
genes deleted and 
partial E3-deletion. 
Tumour necrosis 
factor alpha (TNFα) 
expression regulated 
by radiation-
sensitive promoter 
Early Growth 
Response (Egr-1).  
Phase 
II/III; 304  
Randomly 
assigned 
2:1; 
SOC+TNF
erade:SOC
. 
Intratumoral 
injection by 
percutaneous 
trans-
abdominal or 
endoscopic 
ultrasound. 
Median survival 10.0 
months for both 
treatment arms, n=277.  
 
SOC + TNFerade was 
safe but not effective in 
patients with locally 
advanced pancreatic 
cancer. 
[104, 
173]  
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AdV-tk E1-deleted and 
partial E3-deletion. 
The HSV-tk gene 
expressed from 
CMV 
enhancer/promoter 
with SV40 
polyadenylation 
signal.  
Phase I; 27 CT or 
endoscopic 
ultrasound 
guided 
intratumoral 
injection. 
Safe without toxicity in 
combination with SOC, 
n=24.  
Favourable anti-tumour 
responses and increased 
immune responses. 
[102, 
103] 
AdV-tk E1-deleted and 
partial E3-deletion.  
The HSV-tk gene 
expressed from 
CMV 
enhancer/promoter 
with SV40 
polyadenylation 
signal. 
Phase I/II; 
44 
Intratumoral 
injection. 
Currently recruiting 
patients. 
[103, 
174] 
ETBX-011 E1-, E2B- and E3-
deletions with 
epitopes of human 
CEA expressed 
under control of the 
CMV promoter. 
Phase 
Ib/II; 80 
N/A Ongoing. [105, 
106, 
175, 
176] 
ETBX-011 E1-, E2B- and E3-
deletions with 
epitopes of human 
CEA expressed 
under control of the 
CMV promoter. 
Phase 
Ib/II; 173 
N/A Currently recruiting 
patients. 
[105, 
106, 
175, 
177] 
ETBX-011 E1-, E2B- and E3-
deletions with 
epitopes of human 
CEA expressed 
under control of the 
CMV promoter. 
Phase 
Ib/II; 3 
N/A Ongoing. [105, 
106, 
175, 
178] 
ETBX-011 E1-, E2B- and E3-
deletions with 
epitopes of human 
CEA expressed 
under control of the 
CMV promoter. 
Phase 
Ib/II; 3 
N/A Ongoing.  
 
 
[105, 
106, 
175, 
179] 
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Figure Legends 
Figure 1. Percentage distribution of pancreatic tumours by anatomical site. A diagram 
illustrating the structure of the pancreas as well as its anatomical relation to both the duodenum and 
hepatobiliary tree. Pancreatic tumours can arise at any site within the pancreas and are situated most 
commonly within the head; tumours originating here have the ability to disrupt hepatobiliary 
architecture and disturb the passage of duodenal contents.  
 
Figure 2. Illustration of the 36kb adenovirus type 5 (Ad5) genome with selected genes at 
approximate locations. The first gene to be expressed after viral infection is E1A, which is required 
for viral genome amplification; protein synthesis; and viral replication. The E1A gene products force 
the infected cell into S-phase and drive the expression of other early viral genes including E1B, E3 
and E4. These genes are essential for preventing premature apoptosis by directly inhibiting the G1/S-
checkpoint (E1B); the host antiviral immune defense (E3); and DNA-damage repair mechanisms 
(E4). The E3 immunomodulatory domain codes for E3-12.5K; E3-6.7K; E3gp19K; the adenovirus 
death protein (ADP); the E3B proteins RIDα and β; and E3-14.7K — the main functions are indicated 
in the figure. The viral DNA polymerase (Pol) and the precursor terminal protein (pTP) are encoded 
by the E2B genes, and the viral DNA-binding protein (DBP) is transcribed from the E2A gene. Both 
E2A and E2B proteins are essential for viral DNA synthesis. VA-RNAs inhibit the cellular protein 
kinase R (PKR) that is activated in response to viral infection. Following viral genome synthesis, viral 
late gene expression is initiated from the major late promoter (MLP). The late genes 1-5 (L1–5) code 
for structural proteins essential for virion assembly, including penton (L2), hexon (L3), fiber (L5) and 
the viral protease (L3; Pr). The LITR and RITR indicate the left and right inverted terminal repeats, 
respectively, and Ψ is the packaging sequence. Transgenes are often inserted to replace one or both of 
the E1B19K- and E1B55K-genes. More frequently, transgenes are inserted to replace the entire E3-
genome or specific E3-genes such as the E3B- or the E3gp19K-genes. * Indicates regions frequently 
deleted in the viral coding genes to generate oncolytic replication-selective adenoviral mutants 
(E1ACR2 and E1B55K) and/or enhance the potency (E1B19K and E3gp19K). # Indicates viral 
promoters frequently exchanged for cancer-specific promoters for selective viral replication in 
tumours. € Indicates sites used to change cellular tropism of the fiber protein, for example by de-
targeting of CAR-binding and retargeting to cancer-specific receptors. See text for examples of viral 
modifications. 
Abbreviations: MHC, major histocompatibility complex; EGFR, epidermal growth factor receptor; 
TRAIL, TNF-related apoptosis inducing ligand. 
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Highlights 
 
• Metastatic PDAC is incurable due to the late presentation of symptoms and rapid 
development of resistance to all current therapeutics. It is a cancer of unmet medical 
need with no significant improvements in survival over the last 40 years.  
• PDAC is characterised by numerous genetic alterations resulting in deregulation of 
cell cycle and growth control and expression of cell surface proteins that are not 
present in normal cells. Adenoviral mutants have been engineered to complement and 
utilise the altered genetic programme in PDAC cells and have emerged as a promising 
new strategy to overcome drug resistance.  
• Adenoviral mutants penetrate the dense tumour stroma that frequently contribute to 
tumour growth paving the way for drugs and tumour infiltrating immune cells.   
 
